47 completed. 47 Phase 2, 5 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 47 | Completed 47 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 4 | Completed 4 |
Follow Erectile Dysfunction: new trials by email Literature Review of Erectile Dysfunction trials Research Report on Erectile Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Double-Blind Clinical Study of Intracavernosal OnabotulinumtoxinA Injection in Patients With Erectile Dysfunction Refractory to Phosphodiesterase-5 Inhibitors OnabotulinumtoxinA (Botox ®) Injections, Saline (0.9% NaCl) - Erectile Dysfunction | Phase 2 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 114 | 2024-11-25 | 2026-09-22 |
| Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile Dysfunction LIB-01, LIB-01 Placebo - Erectile Dysfunction | Phase 2 | Completed | Dicot AB | 156 | 2024-11-08 | 2025-08-24 |
| Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction Tadalafil 5mg - Erectile Dysfunction | Phase 2 / Phase 3 | Completed | Ain Shams University | 75 | 2024-01-15 | 2026-08-12 |
| Pharmacodynamic Study of TPN171H Tablets in Patients With Mild to Moderate Erectile Dysfunction TPN171H 2.5mg, TPN171H 5mg, TPN171H 10mg - Erectile Dysfunction | Phase 2 | Completed | Vigonvita Life Sciences | 84 | 2022-08-01 | 2023-02-23 |
| Efficacy of Intracavernosal as add-on Therapy to Sildenafil 100 mg on Demand Compared to Sildenafil 100 mg on Demand for the Treatment of Erectile Dysfunction (ED) Not Sufficiently Responsive to Standard Therapy With Phosphodiesterase Type 5 Inhibitors Investigational product administration Xeomin® (MERZ PHARMACEUTICALS GMBH), Placebo administration - Erectile Dysfunction | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 226 | 2022-03-18 | 2024-12-04 |
| Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients IP2018, Placebo - Erectile Dysfunction | Phase 2 | Completed | Initiator Pharma | 24 | 2020-12-30 | 2026-11-06 |
| Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously Cellgram-ED - Erectile Dysfunction | Phase 2 | Completed | Pharmicell Co., Ltd. | 54 | 2020-10-19 | 2026-02-09 |
| Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction TPN171H, placebo - Erectile Dysfunction | Phase 2 | Completed | Vigonvita Life Sciences | 255 | 2020-07-23 | 2023-06-22 |
| Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction. Autologous Platelet Rich Plasma, Saline solution - Erectile Dysfunction | Phase 2 | Completed | University of Miami | 61 | 2020-05-21 | 2024-01-09 |
| Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer Atorvastatin, Pentoxifylline, Vitamin E Compound - Male Erectile Disorder, Prostate Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 14 | 2019-11-20 | 2023-10-17 |
| A Comparative Pharmacokinetic and Pharmacodynamic Study of Sildenafil in Adult Smokers and Non Smokers Sildenafil 50 mg Oral Tablet - Erectile Dysfunction, Smoking | Phase 1 / Phase 2 | Completed | Ain Shams University | 36 | 2019-06-11 | 2019-09-24 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
| Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy Placebo, Erythropoietin (EPO) - Prostate Cancer, Erectile Dysfunction | Phase 2 | Completed | Johns Hopkins University | 56 | 2017-07-01 | 2021-04-08 |
| Botulinum Toxin for Erectile Dysfunction Botulinum Toxin Type A, Normal saline - Sexual Dysfunction, Erectile Dysfunction | Phase 2 / Phase 3 | Completed | Cairo University | 70 | 2017-01-03 | 2020-01-07 |
| Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction saline injection, Botulinum toxin type A 50 units, Botulinum toxin type A 100 units - Erectile Dysfunction, Botulinum Toxin | Phase 2 | Completed | Benha University | 200 | 2016-07-12 | 2019-11-26 |
| Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction TD0025, Sildenafil Citrate 50mg - Erectile Dysfunction | Phase 2 / Phase 3 | Completed | Vietstar Biomedical Research | 168 | 2016-05-01 | 2018-10-11 |
| Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men Bupropion hydrochloride sustained-release, placebo - Sexual Dysfunctions, Psychological, Hypoactive Sexual Desire Disorder | Phase 2 | Completed | University of Malaya | 80 | 2015-12-01 | 2019-08-01 |
| Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED) Glyceryl trinitrate, MED Placebo - Erectile Dysfunction | Phase 2 | Completed | Futura Medical Developments Ltd. | 232 | 2015-05-15 | 2020-02-12 |
| Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction Intracavernosal administration of autologous ADRC, Liposuction, ADRC isolation - Erectile Dysfunction, Impotence, Vasculogenic | Phase 1 / Phase 2 | Completed | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 12 | 2015-04-01 | 2016-11-30 |
| Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection), Placebo (PBS-20% sucrose) - Erectile Dysfunction | Phase 2 | Completed | Urovant Sciences GmbH | 26 | 2015-04-01 | 2019-08-08 |
Showing 20 of 47. Sign in to see all of them.
Prostatic Neoplasms (5) · Sexual Dysfunction, Physiological (4) · Hypogonadism (3) · Sexual Dysfunctions, Psychological (2) · Diabetes Mellitus, Type 2 (1) · Ejaculatory Dysfunction (1) · Epilepsy (1) · Impotence, Vasculogenic (1) · Lower Urinary Tract Symptoms (1) · Multiple Endocrine Neoplasia Type 1 (1) · Radiation Injuries (1) · Rectal Neoplasms (1) · Seizures (1) · Sigmoid Neoplasms (1)
Genital Diseases (47) · Genital Diseases, Male (47) · Male Urogenital Diseases (47) · Mental Disorders (47) · Urogenital Diseases (47) · Sexual Dysfunctions, Psychological (45) · Sexual Dysfunction, Physiological (43) · Neoplasms (7) · Neoplasms by Site (7) · Genital Neoplasms, Male (5) · Prostatic Diseases (5) · Urogenital Neoplasms (5) · Endocrine System Diseases (4) · Gonadal Disorders (3) · Pathological Conditions, Signs and Symptoms (3)
Sildenafil Citrate (5) · Tadalafil (4) · Vardenafil Dihydrochloride (4) · Botulinum Toxins, Type A (2) · Injections (2) · Saline Solution (2) · Sodium Chloride (2) · udenafil (2) · 1-((1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl)carbonyl)-3,5-dimethyl-4-phenylpiperidin-4-ol (1) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · Anastrozole (1) · ArginMax (1) · Arginine (1) · Atorvastatin (1) · BAY 60-4552 (1)
Pfizer (4) · Bayer (3) · Ain Shams University (2) · Eli Lilly and Company (2) · Johns Hopkins University (2) · Vigonvita Life Sciences (2) · American Medical Systems (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda USL Modena (1) · Benha University (1) · Beth Israel Deaconess Medical Center (1) · CHU de Quebec-Universite Laval (1) · Cairo University (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · Clinica Universidad de Navarra, Universidad de Navarra (1)
United States (16) · France (4) · South Korea (4) · United Kingdom (4) · Canada (3) · Egypt (3) · China (2) · Germany (2) · Italy (2) · Netherlands (2) · Norway (2) · Spain (2) · Sweden (2) · Denmark (1) · Finland (1)
Abdelrahman A Hassan, Msc (1) · Alvaro Morales, MD FRCSC (1) · Andre-Guy Martin, MD (1) · Andrew Herzog, M.D., M.Sc. (1) · Andrey A Pulin, MD, PhD (1) · Anne Yee (1) · Antonella Favit-Van Pelt, MD, PhD (1) · Arthur L Burnett, M.D., M.B.A. (1) · Chad Tang (1) · Chungsu Kim, Ph.D (1) · Dana A Ohl, MD (1)
PMID 19473458, PMID 25974235, PMID 26158605, PMID 26439886, PMID 28480661, PMID 28753830, PMID 33530745, PMID 35448895, PMID 38224135, PMID 40971935, PMID 42114123, PMID 42725809
U10CA081851 (1)